Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
- Recent advances in cancer research have led to new therapies to treat the disease. It is important to continue these advances and discover new ones. To do that, researchers need tissue samples from solid tumors. This study will collect such samples from people already scheduled to have a procedure at the National Institutes of Health Clinical Center (NIHCC).
- To collect tissue samples for use in studying new ways to treat tumors.
- Adults 18 years and older, with a precancerous or cancerous solid tumor who are scheduled to have surgery or a biopsy at the NIHCC.
- Before their procedure, participants will have a small blood sample taken.
- Some participants will undergo leukapheresis. In this procedure, blood is removed through a tube in one arm and circulated through a machine that removes white blood cells. The blood, minus the white blood cells, is returned through a tube in the other arm. The procedure takes 3 4 hours.
- For all participants, during the surgery or biopsy, pieces of the tumor and pieces of normal tissue near it will be removed for this study. The rest of the tumor or precancerous growth will be sent to a lab for analysis.
- Participants will return to the clinic about 6 weeks after the operation for a routine checkup. Some may have to return for additional follow-up.
Bile Duct Cancer
|Study Design:||Time Perspective: Prospective|
|Official Title:||Tumor, Normal Tissue and Specimens From Patients Undergoing Evaluation or Surgical Resection of Solid Tumors|
- Collect biologic samples for premalignant, primary or metastatic solid tumors for the purpose of identifying novel molecular and biologic therapeutic targets [ Time Frame: 10 years ] [ Designated as safety issue: No ]
- To collect detailed history, demographic, treatment data, and perioperative findings in order to categorize and track the specific procedures and outcomes [ Time Frame: 10 years ] [ Designated as safety issue: No ]
|Study Start Date:||July 2013|
|Estimated Study Completion Date:||June 2024|
|Estimated Primary Completion Date:||June 2024 (Final data collection date for primary outcome measure)|
- Recent advances and insights into the molecular pathogenesis of cancer have led to the development of novel molecular and biologic targeted therapies for the treatment of advanced cancer patients. A critical challenge in extending these studies involves the identification and validation of new therapeutic targets for future cancer therapies.
- As Surgical Oncologists at the NCI, we have an interest in identifying novel molecular and biologic targets to facilitate the development of future cancer therapies. In addition, we have the primary responsibility for providing surgical consultative services to the NIH. As such, we are uniquely positioned to acquire and perform important studies on solid tumor tissue to help identify therapeutic targets that may have significant clinical ramifications.
- Primary Objective: To collect biologic samples from patients undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors for the purpose of identifying novel molecular and biologic therapeutic targets
- Secondary Objectives: To collect detailed history, demographic, treatment data, and perioperative findings in order to categorize and track the specific procedures and outcomes.
- Patients greater than or equal to 18 years of age with radiographic evidence of, biochemical evidence of, or histologically/cytologically proven solid neoplasms who require diagnostic or therapeutic intervention as a part of the diagnosis and /or standard of care treatment and/or follow up for their neoplasm
- Patients must have laboratory and physical examination parameters within acceptable limits by standard of practice guidelines prior to planned intervention
- A tissue acquisition trial in which tissues will be obtained at the time of intervention
- Tissue and blood will be processed at the time of collection, stored and then transferred to Dr. Rudloff s laboratory for further processing.
- No investigational therapy will be given.
- It is anticipated that 1000 patients will be enrolled over a period of 10 years
Please refer to this study by its ClinicalTrials.gov identifier: NCT01915225
|Contact: Marybeth S Hughes, M.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact NCI/Surgery Branch Recruitment Center 866-820-4505 email@example.com|
|Principal Investigator:||Marybeth S Hughes, M.D.||National Cancer Institute (NCI)|